Long COVID Treatment Trial-Tirzepatide (LoCITT-T)

Overview:
An estimated 400 million people across the world have Long COVID. So far there has been little research and few effective treatments available. The Long COVID Treatment Trial Tirzepatide (LoCITT-T), sponsored by Scripps Research, will see if a medicine called tirzepatide helps people with Long COVID feel better and could help millions of people living with Long COVID today. Participation can be completed entirely from home, no in-person visits needed.

Study Type:
Mixed Methods

IRB Approved:
Yes

Target Audience:
Adults (18 years and older), living in the U.S. (excluding Hawaii), documentation of Long COVID diagnosis and other inclusion criteria.

How to Apply:
Click the link 

Study Contact:
LoCITT Study Team
longcovid-t@scripps.edu